Janet Gray
Psychiatry · Richmond, INNPI 1497765218
Payments from drug & device makers
Across 100 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$260
- Teva Pharmaceuticals USA, Inc.$250
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- Vanda Pharmaceuticals Inc.$146
- Alkermes, Inc.$141
- Neurocrine Biosciences, Inc.$126
- plus $666 from 13 others
What the payments were for
- Food & beverage$1,52586%
- Education$25114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 18 | $260 |
| Teva Pharmaceuticals USA, Inc. | 5 | $250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $188 |
| Vanda Pharmaceuticals Inc. | 6 | $146 |
| Alkermes, Inc. | 8 | $141 |
| Neurocrine Biosciences, Inc. | 8 | $126 |
| AbbVie | 7 | $121 |
| Johnson & Johnson | 5 | $92 |
| Acadia Pharmaceuticals Inc | 1 | $89 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Lundbeck LLC | 4 | $67 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
| Noven Therapeutics, LLC | 2 | $39 |
| Indivior Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Corium, LLC | 1 | $16 |
| Neos Therapeutics, LP | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$1,777 in reported general payments places this provider in the 75th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 130 | $616,751 |
| Austedo XrDeutetrabenazine | 16 | $206,041 |
| IngrezzaValbenazine Tosylate | 16 | $120,679 |
| VraylarCariprazine Hcl | 36 | $50,986 |
| TrintellixVortioxetine Hydrobromide | 26 | $18,886 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $10,931 |
| Adderall XrDextroamphetamine/Amphetamine | 23 | $7,305 |
| Asenapine Maleate | 27 | $6,245 |
| Oxcarbazepine | 71 | $4,575 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $4,491 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $3,508 |
| Aripiprazole | 35 | $2,803 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $2,799 |
| Clozapine | 26 | $2,752 |
| Ziprasidone Hcl | 33 | $2,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $250 | $822,793146 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $126 | $120,67916 claims |
| AbbVieVraylar | $121 | $50,98636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Richmond
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$788K
- Christopher BojrabCarmel$714K
- Joseph FanelliMunster$443K
- Anantha ShekharIndianapolis$433K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Elizabeth MartinMarion$159K
- Leslie HulvershornIndianapolis$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.